Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis

Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis

The recent introduction of ABP 501, an adalimumab biosimilar, in the treatment of rheumatic diseases was supported by a comprehensive comparability exercise with its originator. On the other hand, observational studies comparing adalimumab and ABP 501 in inflammatory arthritis are still lacking. The...

Full description

Bibliographic Details
Main Authors: Andrea Becciolini, Simone Parisi, Rosalba Caccavale, Elena Bravi, Federica Lumetti, Romina Andracco, Alessandro Volpe, Lucia Gardelli, Francesco Girelli, Eleonora Di Donato, Daniele Santilli, Gianluca Lucchini, Maria Chiara Ditto, Ilaria Platè, Eugenio Arrigoni, Flavio Mozzani, Michele Riva, Antonio Marchetta, Enrico Fusaro, Gilda Sandri, Carlo Salvarani, Marino Paroli, Alarico Ariani
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Journal of Personalized Medicine
Subjects:
rheumatoid arthritis
psoriatic arthritis
axial spondylarthritis
adalimumab
ABP 501
Online Access:https://www.mdpi.com/2075-4426/12/3/335

Internet

https://www.mdpi.com/2075-4426/12/3/335

Similar Items